Moffitt: Researchers Develop Genetic Test that Predicts which Pancreatic Cancer Patients will Benefit from Surgery

Moffitt: Researchers Develop Genetic Test that Predicts which Pancreatic Cancer Patients will Benefit from Surgery

Moffitt: Researchers Develop Genetic Test that Predicts which Pancreatic Cancer Patients will Benefit from Surgery

TAMPA, Fla. – Pancreatic cancer, a highly lethal malignancy, is the fourth most common cause of cancer-related mortality in the United States.  Approximately 25 percent of patients with early cancers undergo potential curative treatment with surgery and chemotherapy. Unfortunately, only about 30 percent of patients who receive this intervention experience long-term cure.Part of this high mortality rate is attributed to a lack of effective diagnostic and prognostic tests. Researchers at Moffitt Cancer Center have utilized modern advanced technology and developed a prognostic test that can determine which early-stage pancreatic cancer patients will have a better outcome following surgery.

Related posts

UNF physics lecturer receives U.S. Patent

Nirmalkumar Patel, a University of North Florida physics associate lecturer, received a U.S. Patent for…

UNF professor reports on returning to exercise post-pandemic, staying healthy in the new year

Dr. James Churilla, UNF professor and Exercise Science and Chronic Disease Graduate Program director, recently…

FIT Biochemist Studies Farming on Mars

Farming on Mars will be a lot harder than ‘The Martian’ made it seem.  Growing…